Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Recent Development of Aminoacyl tRNA Synthetase Inhibitors for Human Diseases: A Future Perspective.

Version 1 : Received: 30 October 2020 / Approved: 2 November 2020 / Online: 2 November 2020 (09:09:37 CET)

How to cite: Kim, S.; Bae, S.; Song, M. Recent Development of Aminoacyl tRNA Synthetase Inhibitors for Human Diseases: A Future Perspective.. Preprints 2020, 2020110005 (doi: 10.20944/preprints202011.0005.v1). Kim, S.; Bae, S.; Song, M. Recent Development of Aminoacyl tRNA Synthetase Inhibitors for Human Diseases: A Future Perspective.. Preprints 2020, 2020110005 (doi: 10.20944/preprints202011.0005.v1).

Abstract

Aminoacyl-tRNA synthetases (ARSs) are essential enzymes for translating amino acids for protein synthesis. Their function in pathogen-derived infectious diseases has been well established, which has led to development of small molecule therapeutics. The applicability of ARS inhibitors for other human diseases such as fibrosis has recently been explored in the clinical setting. There are active studies to find small molecule therapeutics for cancers. Studies on central nervous system (CNS) disorders are burgeoning as well. In this regard, we present a concise analysis of the recent development of ARS inhibitors based on small molecules from the discovery research stage to clinical studies as well as a recent patent analysis from the medicinal chemistry point of view.

Subject Areas

aminoacyl-tRNA synthetase, small molecule inhibitors, human diseases

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.